This Article Full Text Full Text (PDF) All Versions of this Article: 39/10/2891    most recent STROKEAHA.107.505875v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chou, S. H.-Y. Articles by Ayata, C. Search for Related Content PubMed PubMed Citation Articles by Chou, S. H.-Y. Articles by Ayata, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Statins Related Collections Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Other Stroke Treatment - Medical

(Stroke. 2008;39:2891.)
© 2008 American Heart Association, Inc.

Research Letters

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Simvastatin in Aneurysmal Subarachnoid Hemorrhage

Sherry H.-Y. Chou, MD, CM; Eric E. Smith, MD, MPH, FRCPC; Neeraj Badjatia, MD, MSc; Raul G. Nogueira, MD; John R. Sims, II, MD; Christopher S. Ogilvy, MD; Guy A. Rordorf, MD Cenk Ayata, MD

From the Department of Neurology (S.H.-Y.C.), Brigham and Women’s Hospital, Harvard Medical School, and the Departments of Neurology (E.E.S., R.G.N., J.R.S., G.A.R., C.A.), Radiology (R.G.N., J.R.S., C.A.), and Neurosurgery (C.S.O.), Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass; and the Department of Neurology and Neurosurgery (N.B.), Columbia University College of Physicians and Surgeons, New York.

Correspondence to Cenk Ayata, MD, 149 13th street, Room 6408, Charlestown, MA 02129. E-mail cayata{at}partners.org

Background and Purpose— Studies suggest statins ameliorate aneurysmal subarachnoid hemorrhage (SAH)-induced cerebral vasospasm and ischemic complications. We tested safety and feasibility of simvastatin 80 mg/d for vasospasm prevention in SAH patients.

Methods— Thirty-nine statin-naïve Fisher grade 3 SAH subjects were double-blind randomized to receive simvastatin 80 mg/d (n=19) or placebo (n=20), stratified by Hunt and Hess grade. Primary end points were death and drug morbidity.

Results— Mortality was 3/20 in the placebo and 0/19 in the simvastatin group. Study drug was withdrawn in 1 subject in each treatment group for reversible liver enzyme or creatine phosphokinase elevation. Angiographically-confirmed vasospasm occurred in 8/20 placebo and 5/19 simvastatin-treated subjects. Vasospasm-related ischemic infarcts developed in 5/20 placebo and 2/19 simvastatin-treated subjects.

Conclusion— Simvastatin for the prevention of delayed cerebral ischemia is safe and feasible after SAH. A larger study is needed to test its efficacy.

Key Words: vasospasm • delayed cerebral ischemia • clinical trial

This article has been cited by other articles:

				V. Prinz and M. Endres The Acute (Cerebro)Vascular Effects of Statins Anesth. Analg., August 1, 2009; 109(2): 572 - 584. [Abstract] [Full Text] [PDF]

				A. H. Kramer Statins in the Management of Aneurysmal Subarachnoid Hemorrhage--Not (Yet) a Standard of Care Stroke, March 1, 2009; 40(3): e80 - e81. [Full Text] [PDF]

				J. J. Perry Response to Letters by Cook and Hessel, and Kramer Stroke, March 1, 2009; 40(3): e82 - e82. [Full Text] [PDF]